Ampliphi Biosciences (APHB) Stock Price, News & Analysis

Company Overview

AmpliPhi Biosciences was a clinical-stage biotechnology company developing bacteriophage-based therapies for bacterial infections, including infections caused by antibiotic-resistant bacteria. Bacteriophages are viruses that target and infect specific bacteria, and the company pursued them as a potential complement or alternative to conventional antibiotics.

Its investigational programs included AB-PA01, a bacteriophage cocktail targeting Pseudomonas aeruginosa, and AB-SA01, aimed at Staphylococcus aureus. These programs were being developed for serious infections, including those affecting the lungs.

In 2019, AmpliPhi combined with C3J Therapeutics and the resulting company became Armata Pharmaceuticals. AmpliPhi therefore no longer operates as a separate publicly traded company under its former name.

Key Stats

• Today's Range: $3.54 to $3.90
• 50-Day Range: $2.78 to $5.84
• 52-Week Range: $0.15 to $1.37
• Volume: 105,069 shs
• Average Volume: 842,200 shs
• Market Capitalization: $124.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:APHB
• Previous Symbol: AMEX:APHB
• CIK: 921114
• Web: www.ampliphibio.com
• Phone: +1-804-8272524
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,469,000
• Free Float: N/A
• Market Cap: $125.51 million
• Optionable: Not Optionable
• Beta: N/A